Comparison of Efficacy, Safety, and Tolerability of ITCA 650 to Empagliflozin and Glimepiride as add-on Metformin

Inclusion Criteria: * Diagnosis of T2D 3 months prior to the Screening Visit. * Body mass index (BMI) between ≥25 to ≤45 kg/m2 at the Screening Visit. * Glycosylated hemoglobin A1c (HbA1c) ≥7.5 and ≤10.5%. 5. 6. On a stable (3 months prior to the Screening Visit) treatment regimen of metformin monotherapy of ≥1500 mg/day). Exclusion Criteria: * History of type 1 diabetes. * Prior participation in a clinical study involving ITCA 650. * Treatment with any GLP-1 receptor agonist (eg, liraglutide, exenatide) within 6 months prior to Screening. * History or evidence, within the last 6 months prior to the Screening Visit, of myocardial infarction, coronary revascularization (coronary artery bypass grafting or percutaneous coronary intervention), unstable angina, or cerebrovascular accident or stroke. * History or evidence of acute or chronic pancreatitis. * History of medullary thyroid cancer or a family or personal history of multiple endocrine neoplasia type 2. * Treatment of medications that affect GI motility. * History of hypersensitivity to exenatide, empagliflozin, or glimepiride or to one of its excipients. * Women that are pregnant, lactating, or planning to become pregnant. * Chronic (\>10 consecutive days) treatment with systemic corticosteroids within 8 weeks prior to screening.